Lower than you think — and the evidence points at 6 mg or below, not at the top of the shelf. In the one randomised crossover that gave adults who smoke a 3 mg and a 6 mg pouch alongside their own cigarette, the 6 mg pouch delivered more plasma nicotine at thirty minutes than the cigarette did. What it could not match was the speed.
The instinct is obvious: twenty a day is a lot of nicotine, so buy a lot of nicotine. The measured answer is that a mid-tier pouch already meets or beats a cigarette on the amount, and that the thing a cigarette gives you which no pouch gives you — a peak in seven to nine minutes — is not something you can buy your way to with a bigger number. This page sets out what is actually measured, in people who actually smoke, and is honest about where that evidence stops.
One boundary first, because it shapes everything below. Nothing here is advice to switch, and a nicotine pouch is not an approved treatment for anything. The evidence on pouches and quitting is on its own page, and the practical walkthrough for a first pouch when you are coming off cigarettes is here. This page is the strength question only.
What you are actually replacing, in milligrams
Start with the number that matters, which is not the one printed on a cigarette packet. From Benowitz, Hukkanen and Jacob’s pharmacology review: “An average tobacco rod contains 10–14 mg of nicotine”, and “on average about 1–1.5 mg of nicotine is absorbed systemically during” smoking. Most of a cigarette’s nicotine is destroyed or never leaves the rod.
So a twenty-a-day smoker is absorbing somewhere in the region of 20 to 30 mg of nicotine a day. The same review anchors that from the other end: “a cotinine level of 30 ng ml⁻¹ in blood corresponds on average to a nicotine intake of 24 mg per day.” And the concentrations that intake produces are measured: “Blood or plasma nicotine concentrations sampled in the afternoon in smokers generally range from 10 to 50 ng ml⁻¹. Typical trough concentrations during daily smoking range between 10 and 37 ng ml⁻¹ and typical peak concentrations range between 19 and 50 ng ml⁻¹.”
Hold that against what the licensed replacements do. The same table reports that “typical steady-state plasma nicotine concentrations with nicotine patches range from 10 to 20 ng ml⁻¹, and for nicotine gum, inhaler, sublingual tablet, and nasal spray from 5 to 15 ng ml⁻¹”. The authorised products sit at or below a smoker’s trough. That is the gap a heavy smoker is trying to close, and it is worth knowing that the regulated options have never closed it either.
The research was funded by US Public Health Service grants from the National Institute on Drug Abuse, with no declared industry money.
Who counts as “heavy”, and why the question matters here
“Heavy smoker” has a measured meaning. The Heaviness of Smoking Index is a two-item instrument built from cigarettes per day and how soon after waking you light the first one, scored 0 to 6 — “the HSI provides a rapid assessment of smoking intensity-related addiction severity”, with thresholds in common use of 3 or more for screening and 4 or more as a marker of severe dependence. I read that description from a later paper rather than the 1989 and 1991 originals, which sit behind a paywall; the instrument is attributed to Heatherton and colleagues.
This matters because of what it does to the evidence base. Every study below sits at a mean of fifteen to seventeen cigarettes a day, and the entry criteria are lower still — one required participants only to “smoke five or more cigarettes per day for longer than the past 30 days”. On the HSI framing those are moderate smokers. If you are at thirty a day with your first cigarette inside five minutes of waking, nobody has studied you. That is the single most important caveat on this page, and no amount of reading gets around it.
The study that actually answers the question
Keller-Hamilton and colleagues ran a single-blind, three-visit randomised crossover in thirty adults who smoke, in rural Ohio, each tobacco-abstinent for at least twelve hours. Three conditions: a 3 mg ZYN wintergreen pouch, a 6 mg ZYN wintergreen pouch, and the participant’s own usual cigarette. The two pouch strengths were chosen because their pH is similar, which isolates the nicotine concentration rather than the free-base fraction. Participants smoked 16.8 cigarettes a day on average.
The result:
“At t = 30 minutes, mean [95% confidence interval (CI)] plasma nicotine concentrations were 9.5 ng/ml (7.1, 11.9 ng/ml) for the 3 mg nicotine concentration ONP, 17.5 ng/ml (13.7, 21.3 ng/ml) for the 6 mg nicotine concentration ONP and 11.4 ng/ml (9.2, 13.6 ng/ml) for the cigarette.”
Read the middle figure against the last. The 6 mg pouch delivered about half again as much nicotine as the participants’ own cigarettes at the half-hour mark. The 3 mg pouch landed just under the cigarette. And the authors’ conclusion names the thing the numbers do not show:
“Among adult smokers, using 6-mg nicotine concentration oral nicotine pouches (ONPs) was associated with greater plasma nicotine delivery at 30 minutes than 3-mg ONPs or cigarettes, but neither ONP relieved craving symptoms at 5 minutes as strongly as a cigarette. Accelerating the speed of nicotine delivery in ONPs might increase their misuse liability relative to cigarettes.”
That is the whole shape of the problem in one sentence. The milligram number buys you the dose. It does not buy you the five-minute relief, and buying a bigger number does not fix a timing problem. If you want that distinction in full, it is nicotine delivery versus nicotine content.
This study was funded by the National Institute on Drug Abuse and the National Cancer Institute, is registered as NCT05236894, and declares no competing interests. It is the cleanest evidence on this page.
Within one brand, the ladder behaves itself
Altria ran a seven-way crossover in thirty dual users of cigarettes and moist smokeless tobacco, mean 15.3 cigarettes a day, comparing on! pouches at 1.5, 2, 3.5, 4 and 8 mg against each participant’s own cigarette and own smokeless brand:
“The mean nicotine C max for NPs increased with nicotine level, ranging from 3.5 ng/mL (1.5 mg NP) to 15.4 ng/mL (8 mg NP), compared with 12.2 ng/mL for OBCs and 9.8 ng/mL for OBMST. Nicotine t max was much longer for all NPs and OBMST (32.5–34.4 min) compared to OBCs (8.5 min).”
Benchmarked against each participant’s own cigarette, the 3.5 and 4 mg pouches were not significantly different on total nicotine over three hours, while “The 1.5, 2, 3.5, and 4 mg NPs resulted in statistically significantly lower (p < 0.05) C max values, while the 8 mg NP resulted in a statistically significantly (p < 0.05) higher C max relative to participants’ OBCs.”
So within one product line: around 4 mg matches a cigarette on the total, and 8 mg exceeds it on both the peak and the total. The study was funded by Altria Client Services LLC and all authors were Altria employees; it carries no trial registration number. The direction is nonetheless consistent with the independent study above.
Across brands, the ladder stops working
This is the part that undoes most strength advice. British American Tobacco ran a crossover in thirty-five dual users of snus and cigarettes, eight days in confinement, pouches held for sixty minutes. Five brands at the 6–10 mg tier, plus the participant’s own cigarette.
The 6 mg on! pouch produced a higher peak plasma nicotine (17.5 ng/mL) than the 10 mg Zyn pouch (11.9 ng/mL). Every pouch’s six-hour total exceeded the cigarette’s. And the authors state the finding flatly: “Plasma nicotine concentration was not associated with the nicotine contents of the NPs.” Within the same label strength, “C max and AUC 0–6h were significantly higher (both p < 0.0001) for the Lyft 10 mg NP as compared with the Zyn 10 mg NP.”
Handle the funding openly: the study “was supported by British American Tobacco (Investments) Limited, the manufacturer of Lyft and Velo smokeless oral nicotine pouches”, and BAT’s own 10 mg product beat a competitor’s 10 mg product. The brand ranking is not independent. The structural finding — that label milligrams do not order delivery across brands — is corroborated by the independent content work below and by the dissolution data, so the direction survives the funding.
Put the two studies together and you get the one sentence worth carrying away: milligrams predict delivery within a product line, and do not predict it across brands. That is why two 6 mg pouches from different brands feel completely different, and why brand strength scales are not interchangeable.
What the authorised oral products do with this question
There is one regulated analogue: nicotine gum and lozenge, approved over-the-counter medicines. Their labelling answers the dosing question with a single criterion, and it is not volume. The gum label says that “if you smoke your first cigarette within 30 minutes of waking up,” then “use 4 mg nicotine gum”; the lozenge mirrors it, and “if you smoke your first cigarette more than 30 minutes after waking up,” then “use 2 mg nicotine lozenge”.
Note what is absent. The phrases “cigarettes per day” and “cigarettes a day” return zero hits in both labels. The cigarettes-per-day threshold lives on the patch — a slow, all-day product — where the rule is “more than 10 cigarettes per day,” then “Use one 21 mg patch/day”. For the fast oral products the question is how soon you reach for the first one, not how many you get through. And the entire authorised oral ladder stops at 4 mg.
Why that logic cannot simply be carried across to a tin of pouches is itself a matter of law. Under 21 CFR 310.544, “Any OTC drug product that is labeled, represented, or promoted as a smoking deterrent is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act), for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing.” A smoking-deterrent claim is what converts a product into a drug needing approval. Pouches are regulated as tobacco products and are approved for no therapeutic use, so the gum’s dosing rule is a useful piece of regulatory reasoning and not a prescription you can apply to a pouch.
The ladder you can actually buy, and where the law stops it
In the United States the ceiling is set by authorisation rather than by a strength cap. FDA’s own list says “There are 67 nicotine pouch products authorized by the FDA” and “These are the only nicotine pouch products that may be lawfully sold in the United States”, with page content current as of 30 October 2026. The top of that list is a single SKU, ZYN ULTRA Smooth 11 mg. Searching the list for “12 mg” and “15 mg” returns nothing.
Products above that do exist on American shelves. Rogue’s own pages advertise a MAX line at 9, 12 and 15 mg, alongside a standard range where “Rogue Nicotine Pouches come in two different nicotine strengths: 3mg and 6mg.” Rogue appears nowhere on FDA’s authorised list. Being absent from the list is not the same as having been refused — FDA does not publish pending applications — but the agency’s own sentence about what may lawfully be sold is quoted above.
In Great Britain the ceiling is simply missing. The Tobacco and Related Products Regulations 2016 cap nicotine at 20 mg per millilitre only for “Nicotine-containing liquid which is presented for retail sale in an electronic cigarette or refill container”. Across the interpretation regulation, regulation 36 and the contents listing, the phrases “nicotine pouch”, “oral nicotine”, “tobacco-free” and “tobacco free” return zero hits. A tobacco-free pouch falls outside the instrument, which is why Velo’s UK range runs to 17 mg while the American legal ceiling is 11. Two different regulatory instruments, not two different judgements about safety. The wider picture is in strength caps by country.
What the manufacturer tells an experienced nicotine user
The company that sells the 17 mg pouch publishes three tiers with guidance attached. Mellow is “Suitable for new VELO users or those preferring milder nicotine delivery.” Intense is “Intended for experienced VELO nicotine users requiring stronger delivery,” and its top two strengths each carry “For experienced users only.”
And then this, on the same page:
“Experienced nicotine users that are new to VELO should still start with Mellow.”
That is a manufacturer with every commercial reason to sell you the strong tin telling an experienced nicotine user who is new to the format to start at 4 to 6 mg. The same page also states: “You should not use this product if you do not already use nicotine.” Set that beside the Keller-Hamilton finding that 6 mg already out-delivered participants’ own cigarettes, and the two lines point the same way.
The tier table
| Tier | What has been measured in people who smoke | Legal status |
|---|---|---|
| 1.5–2 mg | Peak plasma nicotine roughly a third of the participant’s own cigarette; total about 38–53% of it | on! 2 mg authorised in the US; 1.5 mg ZYN sold but not on FDA’s list |
| 3–4 mg | 3 mg pouch 9.5 ng/mL at 30 min vs 11.4 for the cigarette; 3.5–4 mg matched own-cigarette total over three hours | Authorised in the US; the bottom of Velo’s UK ladder |
| 6 mg | 17.5 ng/mL at 30 min, above the participants’ own cigarette; a 6 mg pouch also out-peaked a 10 mg one from another brand | Authorised in the US; the mainstream tier almost everywhere |
| 8–11 mg | 8 mg exceeded own cigarettes on both peak and total; 9 and 10 mg measured only in cross-brand work | Up to 11 mg authorised in the US; 8 mg ZYN sold but not on FDA’s list |
| 12 mg and above | Nothing. No published pharmacokinetic or subjective data in people who smoke exists above 10 mg. | Not authorised in the US; legal in Great Britain, which has no pouch strength cap |
Three holes, stated plainly
First, as above: no study has tested pouch strengths in genuinely heavy smokers. The populations sit at fifteen to seventeen a day. Second, there is no evidence at all above 10 mg in people who smoke — the top two-thirds of the commercial ladder is unstudied, including every product Velo and Rogue sell above that line. Third, nobody has measured what a switching smoker self-selects. All four studies assigned strengths. The one real-world cohort offered a single product, “in three forms: Pouch (6 mg nicotine), Gum (4 mg), and Lozenge (4 mg)”, so it could not observe a choice; it was funded by Rogue Holdings, LLC, it was observational, and “the study was not registered in a trial database by the Sponsor.” Its reduction and quitting figures are not repeated here.
There is one more finding worth knowing, pointing the other way. In a double-blind within-subject study of seventy-three young adults who already use pouches, “high (vs. low) nicotine strength produced statistically significant lower ratings of appeal (b=−8.75, 95% confidence interval [CI]=−15.41, −2.08) and smoothness (b=−7.72, 95% CI=−14.01, −1.44) and higher harshness ratings (b=7.21, 95% CI=1.07, 13.36).” But those were existing pouch users with low dependence, not smokers, and the authors themselves note the contrast with “adult cigarette smokers, NPs with lower nicotine strength was associated with reduced appeal”. The harshness penalty that pushes a young non-smoker down the ladder is less of a deterrent for somebody already smoking twenty a day — which, uncomfortably, is an argument for why a heavy smoker can tolerate a strength that is doing more than they need. That study was supported by FDA and NIDA.
So what do you buy
On the evidence: a 6 mg pouch, from a brand you then stay with, held for the full time rather than swapped for a stronger one after ten minutes. Two reasons. It is the only strength tested in people who smoke that reached or beat their own cigarettes on nicotine, and it is the tier where the largest number of products exist, which matters because changing brand changes delivery more than changing strength does. If 6 mg is unpleasant, 3 mg landed just under a cigarette in the same study and is a real option rather than a consolation. If 6 mg is doing nothing after a fortnight, the honest answer is that you are now outside the evidence and the thing to check first is the hold time and the brand, not the number.
What the evidence does not support is starting at the top. Nothing above 10 mg has been studied in people who smoke at all, the products that exist above that line are there because of a gap in one country’s regulations rather than a finding about who needs them, and the manufacturer of the strongest of them says to start at the bottom.
Common questions
Is a 6 mg pouch “equal to” a cigarette? On nicotine at thirty minutes, in one study, it was more than equal. On speed it is not close: median time to peak was 7 minutes for a cigarette and around 60–65 minutes for pouches in the cross-brand study. Nicotine equivalence goes into this properly.
Does the number on the can mean mg per pouch or mg per gram? Every brand named on this page labels milligrams per pouch. Scandinavian products often label per gram, and the two are not comparable. See mg per pouch vs mg per gram.
Does the can tell the truth? Broadly, on the low side. CDC’s survey of seventy oral nicotine products found “The measured total nicotine content was either equal to or less than the level stated on the label, except for one product”, and “Overall, products advertised as higher strength were found to have higher nicotine content than products advertised as lower strength.” The detail is in measured vs labelled nicotine.
What if I take too much? The familiar “60 mg kills an adult” figure does not survive scrutiny: a 2014 toxicology review traced it to nineteenth-century self-experiments and concluded that “a careful estimate suggests that the lower limit causing fatal outcomes is 0.5–1 g of ingested nicotine, corresponding to an oral LD 50 of 6.5–13 mg/kg.” That is not a reason to be casual, and converting either figure into a number of pouches would be arithmetic of mine rather than a finding of anyone’s. The practical signs are on signs of too much nicotine, and the daily-total question on how much nicotine in a day is too much.
Can I use pouches and keep smoking? You can, and it means the nicotine from both. Nothing on this page is a recommendation to do either. If the direction you want is down rather than across, that is stepping down your strength.
For the whole picture on tiers, including who each one is for, start from the complete mg guide, or go straight to the 6 mg tier. If you want what the first ten minutes will actually be like, two of today’s companion pages are why some pouches burn and others don’t and snus and saliva. And the ranked products are in the master ranking.
Sources
- Keller-Hamilton B et al., Nicotine delivery and craving relief from oral nicotine pouches versus cigarettes, Addiction, 2024. Randomised crossover, n=30 adults who smoke. Funded by NIDA (K01DA055696) and NCI (U54CA287392); NCT05236894; declaration of interests: none.
- Liu J et al., Pharmacokinetics of nicotine pouches at five nicotine levels, Psychopharmacology, 2022. n=30 dual users. “This study was funded by Altria Client Services LLC, and all authors are employees of Altria Client Services LLC.” No trial registration.
- McEwan M et al., A randomised study of nicotine delivery from five oral nicotine pouches, European Journal of Drug Metabolism and Pharmacokinetics, 2022. n=35. “The study was supported by British American Tobacco (Investments) Limited, the manufacturer of Lyft and Velo smokeless oral nicotine pouches.” ISRCTN17828518.
- Benowitz NL, Hukkanen J, Jacob P III, Nicotine chemistry, metabolism, kinetics and biomarkers, Handbook of Experimental Pharmacology, 2009. Supported by US Public Health Service grants DA02277 and DA12393 from NIDA; no conflict-of-interest statement in the chapter.
- Han DH et al., Nicotine strength, pH and the appeal of oral nicotine pouches, Addiction, 2026. Double-blind, n=73 young adults who use pouches. Supported by FDA and NIH/NIDA (K99DA058241); NCT06597435. One author discloses relationships with Pfizer and Johnson & Johnson outside the work.
- Tran H et al., Total and unprotonated (freebase) nicotine content in new types of oral “tobacco-free” nicotine products, Tobacco Control, 2026. CDC authors; “The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.”
- McDowell EH et al., Effect of flavoured Rogue oral nicotine product use on smoking reduction and quitting, BMC Public Health, 2024. Observational, unregistered; “This research was funded by Rogue Holdings, LLC (the Sponsor).” Cited here only for the single 6 mg product used.
- Mayer B, How much nicotine kills a human?, Archives of Toxicology, 2014. No funding or conflict statement in the paper.
- US Food and Drug Administration, Nicotine pouch products authorized by the FDA, page content current as of 30 October 2026, read 4 November 2026.
- 21 CFR § 310.544, from the Electronic Code of Federal Regulations, title 21 as of 30 October 2026.
- National Library of Medicine DailyMed, structured product labelling for nicotine polacrilex gum, nicotine polacrilex lozenge and nicotine transdermal system.
- Tobacco and Related Products Regulations 2016, regulation 36, and regulation 2.
- VELO, UK product range and strength guidance, read 4 November 2026. Company source.
- Rogue, nicotine pouch product pages and Rogue MAX, read 4 November 2026. Company source.
- Charkazi A et al., Heaviness of Smoking Index validation, Addictive Behaviors Reports, 2026 — read for the description of the index only, because the 1989 and 1991 originals are paywalled. Funded by Golestan University of Medical Sciences.
Last verified 4 November 2026.
